In Vitro Effect of Lisinopril on Endothelial Progenitor Cell (Epc) Proliferation from Peripheral Blood of Stable Coronary Artery Disease Patients

Yudi Her Oktoviono, Ragil Nur Rosyadi, Djoko Soemantri

Abstract

Background: EPC has displayed beneficial effects as a biomarker and therapeutic material in coronary artery disease (CAD). Efforts have tried to increase EPC level and function. Recent studies found that angiotensin converting enzyme inhibitor (ACEI) improved circulating EPC in CAD patients. In contrast, angiotensin receptor blocker (ARB) reduced circulating EPC in kidney transplanted patients. This controversial effect suggests that there is a direct effect of ACEI on EPC level beyond the classical renin angiotensin aldosterone system (RAAS) pathway. Methods: This was an in vitro quasi experimental post-test control group study. The MNCs were isolated from peripheral blood of stable coronary artery disease patients and cultured in CFU-Hill medium for 3 days. Samples were put into two groups, i.e. lisinopril group and control group. The lisinopril group was divided into 3 subgroups with different doses, 2 µmol/L, 10 µmol/L, and 50 µmol/L then incubated for 48 hours. EPC proliferation was evaluated afterwards with a MTT cell proliferation assay. An immunocytochemistry method was performed for EPC identification to evaluate expression of CD34+. CFU-Hill were observed to confirm functional characteristics of EPC. Data wasanalyzed using the ANOVA test. Results: The MTT cell proliferation assay showed a significant increase of EPC proliferation in lisinopril groups compared with control group (0.246 ± 0.018 vs.0.168 ± 0.016, p<0.05). It also revealed a significant difference in EPC proliferation between each dose where the high dose showed the highest effect (0.246 ± 0.018 vs. 0.264 ± 0.003 vs 0.282± 0.002, p<0.05). CFU-Hill counts demonstrated better colony number in the lisinopril compared to controlgroup. Immunocytochemistry showed positive expression of CD34. Conclusion: Lisinopril has a direct effect to increase EPC proliferation from peripheral blood of stable coronary artery disease patients. High doses of lisinopril showed the best effect on EPC proliferation.

Download


Paper Citation


in Harvard Style

Oktoviono Y., Rosyadi R. and Soemantri D. (2017). In Vitro Effect of Lisinopril on Endothelial Progenitor Cell (Epc) Proliferation from Peripheral Blood of Stable Coronary Artery Disease Patients.In Proceedings of the International Meeting on Regenerative Medicine - Volume 1: IMRM, ISBN 978-989-758-334-6, pages 53-58. DOI: 10.5220/0007315600530058


in Bibtex Style

@conference{imrm17,
author={Yudi Her Oktoviono and Ragil Nur Rosyadi and Djoko Soemantri},
title={In Vitro Effect of Lisinopril on Endothelial Progenitor Cell (Epc) Proliferation from Peripheral Blood of Stable Coronary Artery Disease Patients},
booktitle={Proceedings of the International Meeting on Regenerative Medicine - Volume 1: IMRM,},
year={2017},
pages={53-58},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0007315600530058},
isbn={978-989-758-334-6},
}


in EndNote Style

TY - CONF

JO - Proceedings of the International Meeting on Regenerative Medicine - Volume 1: IMRM,
TI - In Vitro Effect of Lisinopril on Endothelial Progenitor Cell (Epc) Proliferation from Peripheral Blood of Stable Coronary Artery Disease Patients
SN - 978-989-758-334-6
AU - Oktoviono Y.
AU - Rosyadi R.
AU - Soemantri D.
PY - 2017
SP - 53
EP - 58
DO - 10.5220/0007315600530058